Silence Therapeutics (NASDAQ:SLN – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Valuation & Earnings
This table compares Silence Therapeutics and Connect Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silence Therapeutics | $560,000.00 | 2,123.48 | -$88.61 million | ($1.28) | -15.43 |
| Connect Biopharma | $60,000.00 | 841.91 | -$55.48 million | ($1.19) | -0.67 |
Connect Biopharma has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Silence Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.
Profitability
This table compares Silence Therapeutics and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silence Therapeutics | -8,943.86% | -106.94% | -47.99% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Silence Therapeutics and Connect Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silence Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
Silence Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 21.52%. Connect Biopharma has a consensus target price of $5.88, indicating a potential upside of 632.36%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Silence Therapeutics.
Summary
Connect Biopharma beats Silence Therapeutics on 8 of the 14 factors compared between the two stocks.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
